Johnson & Johnson expands ophthalmology and medical device portfolio
Johnson & Johnson announced plans to acquire drug developer Ollin Biosciences and received regulatory clearance for expanded use of a surgical instrument. These strategic moves aim to strengthen its ophthalmology and medical technology portfolio.
Key points
- Johnson & Johnson announced its intent to acquire Ollin Biosciences.
- The U.S. Food and Drug Administration (FDA) cleared the HARMONIC 1100 ultrasonic shears for a broader range of otolaryngology procedures.
- The financial terms of the Ollin Biosciences deal and its closing date remain unknown.
Acquisition of Ollin Biosciences
Johnson & Johnson announced its intent to acquire Ollin Biosciences. The deal will give the corporation rights to OLN324, a bispecific antibody in Phase 3 clinical trials. The drug is being developed for treating retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.
Expanded clearance for HARMONIC 1100
The U.S. Food and Drug Administration (FDA) cleared the HARMONIC 1100 ultrasonic shears for a broader range of otolaryngology procedures. This decision allows the instrument to be used for more ear, nose, and throat operations in the U.S.
Risks and uncertainties
The financial terms of the Ollin Biosciences deal and its closing date remain unknown. As OLN324 is still in development, the investment's success will depend on clinical trial results and future regulatory approval.
What to watch
Shareholders should watch for official company announcements regarding the Ollin Biosciences deal closing date. It is also important to monitor quarterly earnings reports to assess the impact of the expanded use of HARMONIC 1100 on the medical technology segment's performance.
Original sources
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- Johnson & Johnson Receives FDA Clearance for Expanded U.S. Ear, Nose and Throat (ENT) Indication for HARMONIC™ 1100 Shears
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Johnson & Johnson
A notification in your browser or on your phone when we publish about Johnson & Johnson. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
